Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
22 mai 2024 11h20 HE
|
Kymera Therapeutics, Inc.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting ...
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
22 mai 2024 11h15 HE
|
Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
21 mai 2024 14h30 HE
|
InflaRx N.V.
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data...
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
15 mai 2024 07h00 HE
|
Upstream Bio, Inc.
Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference
Employ Welcomes New Chief Customer Officer
14 mai 2024 07h00 HE
|
Employ Inc.
Employ Welcomes Amanda Berger as New Chief Customer Officer
ClearStar Announces Appointment of Pam Dunsky as Chief Operating Officer
28 févr. 2024 10h47 HE
|
ClearStar
ClearStar appoints Pam Dunsky as Chief Operating Officer (COO) to oversee Client Service and Operations.
ClearStar announces appointment of Mike Pritts as Chief Executive Officer
03 nov. 2023 16h50 HE
|
ClearStar
Alpharetta, Georgia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ClearStar, Inc., a leading provider of modern, integrated, background, drug, and health screening solutions, is pleased to announce the...
Controlled Release Fertilizers Market Surpasses US$ 5.57 billion by 2032, Reflecting Sustained Growth – By PMI
09 oct. 2023 14h00 HE
|
PMI
Covina, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Controlled release fertilizers are granulated fertilizer which help in releasing nutrients with controlled release period into the soil. They are also known...
Urbana Corporation Congratulates Blue Ocean Technologies on its new partnership with the Tokyo Stock Exchange
08 août 2023 11h47 HE
|
Urbana Corporation
/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./ TORONTO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Urbana Corporation ("Urbana" or the “Corporation”) (TSX and CSE: URB, URB.A)...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
03 avr. 2023 07h00 HE
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...